|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsored by: |
Sanofi-Aventis |
| Information provided by: | Sanofi-Aventis |
| ClinicalTrials.gov Identifier: | NCT00124332 |
Purpose
The purpose of this study is to determine if rimonabant 20 mg once daily (od) administered during 18-20 months will reduce progression of coronary atherosclerosis as assessed by intravascular ultrasound (IVUS) when administered on top of standard behavioral and pharmacological therapy given as needed, in patients with abdominal obesity associated with current smoking and/or metabolic syndrome.
| Condition | Intervention | Phase |
|
Coronary Atherosclerosis |
Drug: Rimonabant (SR141716) Drug: Placebo |
Phase III |
| MedlinePlus related topics: | Ultrasound |
| ChemIDplus related topics: | Rimonabant SR 141716A |
| Study Type: | Interventional |
| Study Design: | Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Placebo Control, Parallel Assignment, Safety/Efficacy Study |
| Official Title: | Randomized, Multicenter, Double-Blind, Placebo-Controlled, Two-Arm Parallel Group Trial of Rimonabant 20-mg od, for Inhibition of Atherosclerosis Progression Assessed by IVUS (IntraVascular UltraSounds), in Overweight Patients With Clustering Risk Factors |
| Enrollment: | 839 |
| Study Start Date: | January 2005 |
| Study Completion Date: | October 2007 |
Eligibility
| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contacts and Locations| United States, Ohio | |||||
| The Cleveland Clinic Foundation | |||||
| Cleveland, Ohio, United States, 44195 | |||||
| Australia | |||||
| sanofi-aventis, Australia | |||||
| Macquarie Park, Australia | |||||
| Belgium | |||||
| sanofi-aventis, Belgium | |||||
| Diegem, Belgium | |||||
| Canada | |||||
| Sanofi-Aventis Administrative Office | |||||
| Laval, Canada | |||||
| France | |||||
| sanofi-aventis, France | |||||
| Paris, France | |||||
| Italy | |||||
| sanofi-aventis Italy | |||||
| Milano, Italy | |||||
| Netherlands | |||||
| sanofi-aventis, Netherlands | |||||
| Gouda, Netherlands | |||||
| Poland | |||||
| sanofi-aventis Poland | |||||
| Warszawa, Poland | |||||
| Spain | |||||
| sanofi-aventis Spain | |||||
| Barcelona, Spain | |||||
| Sanofi-Aventis |
| Study Director: | ICD CSD | Sanofi-Aventis |
More Information
| Responsible Party: | sanofi-aventis ( ICD Study Director ) |
| Study ID Numbers: | EFC5827, SR141716 |
| First Received: | July 26, 2005 |
| Last Updated: | July 7, 2008 |
| ClinicalTrials.gov Identifier: | NCT00124332 |
| Health Authority: | United States: Food and Drug Administration |
|
|
|